NEW YORK – The Salk Institute and BrigeBio Pharma announced a three-year collaboration on Wednesday to advance the institute's cancer research.
BridgeBio will fund research at the Salk Cancer Center over the next three years, with the goal of developing new precision oncology treatments based on the institute's research into genetically validated drug targets. The partners did not disclose the funding amount.
The Salk Cancer Center, one of seven National Cancer Institute-designated cancer centers in the US, has two research programs. In one program, researchers are exploring how genetic alterations, epigenetic controls, and the immune system work together to cause cancer, and generating knowledge that may lead to the development of novel diagnostics and therapeutics. In the second program, researchers are using mouse models to study tumor biology and testing out therapies within these model systems.
Salk also leads the Conquering Cancer Initiative, in which researchers are working on finding new treatments for glioblastoma, and pancreatic, ovarian, lung, and triple-negative breast cancers.
California-based BridgeBio develops therapies for genetic diseases. Its pipeline includes a treatment, called infigratinib, which is currently being studied in a randomized, Phase III trial involving urothelial cancer patients with a targetable FGFR3 alteration and in a single-arm, Phase II trial involving patients with FGFR-altered solid tumors.
"BridgeBio is focused on partnering with leading academic institutions to accelerate promising research into clinical studies, with a range of therapeutic modalities such as biologics, gene therapies and small molecules," BridgeBio CEO Neil Kumar said in a statement. "Through this partnership, we look forward to translating exciting academic findings into potential treatments and understanding the impact they may bring to patients."